LINGO1 and myeloid sarcoma: A clinical trial on opicinumab, an antibody against LINGO1 (leucine-rich repeat neuronal protein 1, a surface protein on OPCs inhibiting their differentiation) in patients with relapsing MS did not reach the primary endpoint (i.e., multicomponent disability improvement over 72 weeks) and its development was thus halted, although outcomes may have been assessed too early following the treatment.